Intelligence · Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.
-
Rugonersen
Hoffmann-La Roche
Angelman Syndrome (AS)
1 trial -
Tiragolumab, CISPLATIN , Tecentriq 1 200 mg concentrate for solution for infusion, GEMCITABINE
Hoffmann-La Roche
Urothelial carcinoma (UC)
1 trial -
Trastuzumab
Hoffmann-La Roche
Early Breast Cancer
1 trial -
atorvastatin
Hoffmann-La Roche
Healthy Volunteer
1 trial -
balapiravir [RO4588161]
Hoffmann-La Roche
Dengue
1 trial -
danoprevir
Hoffmann-La Roche
Healthy Volunteer
1 trial -
trastuzumab [Herceptin]
Hoffmann-La Roche
Healthy Volunteer
1 trial -
Atezolizumab
Hoffmann-La Roche
Carcinoma, Non-Small-Cell Lung
1 trial -
Evrysdi 0.75 mg/mL powder for oral solution, RO7034067
Hoffmann-La Roche
Spinal Muscular Atrophy (SMA)
1 trial -
Ganciclovir
Hoffmann-La Roche
Cytomegalovirus Infections
1 trial -
Hemlibra 150 mg/mL solution for injection
Hoffmann-La Roche
Severe or Moderate Hemophilia A
1 trial -
Ocrevus 300 mg concentrate for solution for infusion
Hoffmann-La Roche
Multiple Sclerosis (MS) or Clinically Isolated Syndrome (CIS) [in line with the locally approved indications]
1 trial -
PEG-IFN alfa-2a
Hoffmann-La Roche
Hepatitis C, Chronic
1 trial -
RO7034067, Evrysdi 0.75 mg/mL powder for oral solution
Hoffmann-La Roche
Spinal Muscular Atrophy (SMA)
1 trial -
Satralizumab 120 mg
Hoffmann-La Roche
Neuromyelitis Optica Spectrum Disorder
1 trial -
Vabysmo 120 mg/mL solution for injection
Hoffmann-La Roche
Neovascular Age-Related Macular Degeneration
1 trial -
Vemurafenib
Hoffmann-La Roche
Neoplasms
1 trial -
docetaxel
Hoffmann-La Roche
Breast Cancer
2 trials -
epoetin beta [NeoRecormon]
Hoffmann-La Roche
Anemia
1 trial -
ibandronate [Bonviva/Boniva]
Hoffmann-La Roche
Post Menopausal Osteoporosis
1 trial -
methoxy polyethylene glycol-epoetin beta [Mircera]
Hoffmann-La Roche
Anemia
2 trials -
trastuzumab [Herceptin]
Hoffmann-La Roche
Gastric Cancer
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources